chinese academy of sciences in response to the artemisinin drugs research and development of traditional Chinese medicine patent

"Patent drug artemisinin derivatives

Time: 2015-10-12

Source: China's traditional Chinese medicine

The author: butyl

Report from our correspondent (reporter ding ocean) on October 9, China academy of traditional Chinese medicine held a press conference, the tu and his team of artemisinin drugs patents related to respond. China institute of traditional Chinese medicine academy of sciences, chief researcher Jiang Tingliang said that our country has not related patents and intellectual property protection laws and regulations, although the artemisinin patent right is not in our country, however, artemisinin-based derivative drug development can still apply for the patent.

"Tu and his team discovered artemisinin, but it is not the patent of artemisinin to our country." In all immersed in the joy of tu won a Nobel Prize, such questions has been spread between networks.

Why China is the first discovered artemisinin can treat malaria country, is also the first successful extracting high purity artemisinin country, its patents, but not in China?

In response, the Chinese institute of traditional Chinese medicine academy of sciences, lead researcher Jiang Tingliang responded, "this was no exploitation of the patent law and our country have a certain relationship." In 1984, China promulgated the patent law in China, compared with 1977 artemisinin, 7 years of relevant technical invention it is late for patent protection consciousness is relatively weak at that time. Speak of the patent protection of artemisinin, the then Chinese old, director of the institute of traditional Chinese medicine academy of sciences are those with regrets.

According to Jiang Tingliang artemisinin research results, only in the internal publications issued a small scale in confidential information way, starting in 1977, after approved by the ministry of health in China in the name of "the structure of artemisinin research cooperation" was first published in the journal science bulletin of the chemical structure of artemisinin. But, including subsequently published articles are based on collective signed, no article is a personal signature.

"At that time, our country has not related patents and intellectual property protection laws and regulations, to artemisinin although first found, but can't apply for patent protection from the law Angle. International practice has a regulation, if the inventions in the previously published without patent protection, since can't apply for patent." Jiang Tingliang said.

"We are also considering, later will not be to artemisinin drugs and drug resistance, will not happen after infected. So we add other drugs in artemisinin, can protect the artemisinin active ingredients, can also decrease the rate of redyeing, we call it a compound therapy." Jiang Tingliang believes that the study of drug artemisinin and its derivatives, promising "a long time of China's exports are technical, rather than the preparation, so the statistics of export share is lower than actual, but we are currently of drug patent application related derivatives, believe that artemisinin related research results will be more and more."

"Artemisinin related research to realize industrialization is very important, most domestic artemisinin related businesses have a joint venture, its yield and extract study also quite a lot. Moreover, other researchers are currently studying artemisinin in areas other than some new therapy to treat malaria." China's communist party chief of institute of traditional Chinese medicine academy of sciences xiao-xin zhu, said researchers are trying to artemisinin effect on tumor diseases related to try, "our scientific research work has never interrupted." Zhu Xiao shin.